G1 Therapeutics

G1 Therapeutics CEO’s compensation declines 44.7% in 2017

Posted by WRAL TechWire | Apr 24, 2018

The chief executive officer of G1 Therapeutics Inc. saw a 44.7 percent decline in compensation in 2017, according to a securities filing.

Former GSK CEO Andrew Witty to take a top job with UnitedHealth

Posted by WRAL TechWire | Mar 13, 2018

Andrew Witty is coming out of a brief retirement to become CEO of Optum, which is part of UnitedHealth.

G1 Therapeutics reports positive results for cancer therapy

Posted by Barry Teater | Mar 7, 2018

G1 Therapeutics reports positive top-line data from a Phase 2a trial of its potential therapy for patients who are taking chemotherapy for small-cell lung cancer.

Five CED ‘alumni’ celebrate success stories at Life Science Conference

Posted by Barry Teater | Mar 1, 2018

Five “alumni” companies of the Council for Entrepreneurial Development reported major progress at the CED’s Life Sciences Conference.

Major investor sells $2.6M in G1 Therapeutics stock

Posted by WRAL TechWire | Dec 7, 2017

MedImmune Ventures, a significant investor in G1 Therapeutics, has sold $2.6 million worth of its stake.

RTP-based G1 Therapeutics files for $115M IPO

Posted by WRAL TechWire | Apr 14, 2017

G1 Therapeutics Inc., a clinical-stage biopharmaceutical company based in the Research Triangle Park, filed Thursday for an initial public offering of $115 million. G1 Therapeutics focuses on the discovery and development of novel therapeutics for the treatment of cancer. It plans to use proceeds from the offering to advance...

Data Dump: The 10 Biggest VC Raises & Top Five Exits of 2016

Posted by Amy Huffman | Jan 9, 2017

2016 has come and gone, but numbers—specifically those showing venture capital deal flow and investment amounts—are still trickling in. TBD as to whether final figures will depict a year similar to 2015’s blockbuster fundings or something more akin to NC’s mediocre showing from 2011-2014. But if the most recent...